David W. Dodick

David W. Dodick publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where David W. Dodick sits on this spectrum.

David W. Dodick D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where David W. Dodick sits on this spectrum.

Overview

Best Publications

• A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

  Brian G. Weinshenker;Peter C. O'Brien;Tanya M. Petterson;John H. Noseworthy

  1127
  Citations

• New Appendix Criteria Open for a Broader Concept of Chronic Migraine

  J. Olesen;M -G Bousser;H -C Diener;D. Dodick

  1096
  Citations

• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

  David W. Dodick;Catherine C. Turkel;Ronald E. Degryse;Sheena K. Aurora

  1090
  Citations

• Narrative review: reversible cerebral vasoconstriction syndromes.

  Leonard H. Calabrese;David W. Dodick;Todd J. Schwedt;Aneesh B. Singhal

  1056
  Citations

• Fremanezumab for the Preventive Treatment of Chronic Migraine

  Stephen D. Silberstein;David W. Dodick;Marcelo E. Bigal;Paul P. Yeung

  862
  Citations

• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

  Tony W Ho;Michel D Ferrari;David W Dodick;Vince Galet

  762
  Citations

• A self-administered screener for migraine in primary care: The ID Migraine™ validation study

  Richard B. Lipton;D. Dodick;R. Sadovsky;K. Kolodner

  751
  Citations

• Migraine

  Unknown

  615
  Citations

• Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

  Stephen D. Silberstein;Richard B. Lipton;David W. Dodick;Frederick G. Freitag

  602
  Citations

• ARISE: A Phase 3 randomized trial of erenumab for episodic migraine:

  David W Dodick;Messoud Ashina;Jan Lewis Brandes;David Kudrow

  600
  Citations

• Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial

  Richard B Lipton;David W Dodick;Stephen D Silberstein;Joel R Saper

  543
  Citations

• A Phase‐by‐Phase Review of Migraine Pathophysiology

  David W. Dodick

  496
  Citations

• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

  David W Dodick;Peter J Goadsby;Peter J Goadsby;Stephen D Silberstein;Richard B Lipton

  488
  Citations

• Adherence to oral migraine-preventive medications among patients with chronic migraine:

  Zsolt Hepp;David W Dodick;Sepideh F Varon;Patrick Gillard

  475
  Citations

• Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study

  David W. Dodick;Stephen D. Silberstein;Kenneth L. Reed;Timothy R. Deer

  433
  Citations

• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

  Hong Sun;David William Dodick;Stephen Silberstein;Peter J. Goadsby

  407
  Citations

• Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

  Cristina Tassorelli;Hans-Christoph Diener;David W Dodick;Stephen D Silberstein

  388
  Citations

• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

  Marcelo E Bigal;David W Dodick;Alan M Rapoport;Stephen D Silberstein

  374
  Citations

• Ubrogepant for the Treatment of Migraine.

  David W. Dodick;Richard B. Lipton;Jessica Ailani;Kaifeng Lu

  373
  Citations

• Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine

  David Dodick;Richard B. Lipton;Vincent Martin;Vasilios Papademetriou

  335
  Citations

• A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine:

  Tiffini Voss;Richard B Lipton;David W Dodick;Nicole Dupre

  273
  Citations

• Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

  Richard B. Lipton;David W. Dodick;Jessica Ailani;Kaifeng Lu

  252
  Citations

• OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

  Stephen D. Silberstein;Andrew M. Blumenfeld;Roger K. Cady;Ira M. Turner

  248
  Citations